Literature DB >> 31509236

The IL-13-OVOL1-FLG axis in atopic dermatitis.

Kazuhisa Furue1, Takamichi Ito1, Gaku Tsuji1, Dugarmaa Ulzii1, Yen Hai Vu1, Makiko Kido-Nakahara1, Takeshi Nakahara1,2, Masutaka Furue1,2,3.   

Abstract

Despite sharing interleukin-4 receptor α (IL-4Rα) in their signaling cascades, IL-4 and IL-13 have different functions in atopic inflammation. IL-13 preferentially participates in the peripheral tissues because tissue-resident group 2 innate lymphoid cells produce IL-13 but not IL-4. In contrast, lymph node T follicular helper cells express IL-4 but not IL-13 to regulate B-cell immunity. The dominant microenvironment of IL-13 is evident in the lesional skin of atopic dermatitis (AD). The IL-13-rich local milieu causes barrier dysfunction by down-regulating the OVOL1-filaggrin (FLG) axis and up-regulating the periostin-IL-24 axis. Genome-wide association studies also point to the crucial involvement of the IL-13, OVOL1 and FLG genes in the pathogenesis of AD. Biologics targeting IL-13, such as the anti-IL-4Rα antibody dupilumab and the anti-IL-13 antibody tralokinumab, successfully improve AD lesions and further highlight the importance of IL-13 in the pathogenesis of AD.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  OVOL1; Periostin; atopic dermatitis; filaggrin; interleukin-13

Mesh:

Substances:

Year:  2019        PMID: 31509236      PMCID: PMC6856930          DOI: 10.1111/imm.13120

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  73 in total

1.  Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis.

Authors:  Stephan Weidinger; Elke Rodríguez; Caroline Stahl; Stefan Wagenpfeil; Norman Klopp; Thomas Illig; Natalija Novak
Journal:  J Invest Dermatol       Date:  2006-11-09       Impact factor: 8.551

2.  Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients.

Authors:  Hidehisa Saeki; Shinichi Imafuku; Masatoshi Abe; Yoichi Shintani; Daisuke Onozuka; Akihito Hagihara; Norito Katoh; Hiroyuki Murota; Satoshi Takeuchi; Makoto Sugaya; Miki Tanioka; Sakae Kaneko; Koji Masuda; Takaaki Hiragun; Naoko Inomata; Yuki Kitami; Yuichiro Tsunemi; Shinya Abe; Miwa Kobayashi; Donald E Morisky; Masutaka Furue
Journal:  J Dermatol       Date:  2015-02-27       Impact factor: 4.005

3.  Treatment satisfaction in atopic dermatitis relates to patient-reported severity: A cross-sectional study.

Authors:  T Nakahara; H Fujita; K Arima; Y Taguchi; S Motoyama; M Furue
Journal:  Allergy       Date:  2019-01-17       Impact factor: 13.146

Review 4.  The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines.

Authors:  Hongwei Han; Florence Roan; Steven F Ziegler
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

Review 5.  Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies.

Authors:  Masutaka Furue; Takahito Chiba; Gaku Tsuji; Dugarmaa Ulzii; Makiko Kido-Nakahara; Takeshi Nakahara; Takafumi Kadono
Journal:  Allergol Int       Date:  2017-01-02       Impact factor: 5.836

6.  Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.

Authors:  Andreas Wollenberg; Michael D Howell; Emma Guttman-Yassky; Jonathan I Silverberg; Christopher Kell; Koustubh Ranade; Rachel Moate; René van der Merwe
Journal:  J Allergy Clin Immunol       Date:  2018-06-12       Impact factor: 10.793

7.  Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis.

Authors:  Ellen H van den Bogaard; Judith G M Bergboer; Mieke Vonk-Bergers; Ivonne M J J van Vlijmen-Willems; Stanleyson V Hato; Pieter G M van der Valk; Jens Michael Schröder; Irma Joosten; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

8.  Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).

Authors:  Eric L Simpson; Abhijit Gadkari; Margitta Worm; Weily Soong; Andrew Blauvelt; Laurent Eckert; Richard Wu; Marius Ardeleanu; Neil M H Graham; Gianluca Pirozzi; E Rand Sutherland; Vera Mastey
Journal:  J Am Acad Dermatol       Date:  2016-06-04       Impact factor: 11.527

Review 9.  Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.

Authors:  M Furue; K Yamamura; M Kido-Nakahara; T Nakahara; Y Fukui
Journal:  Allergy       Date:  2017-07-20       Impact factor: 13.146

10.  Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis.

Authors:  Lavinia Paternoster; Marie Standl; Johannes Waage; Hansjörg Baurecht; Melanie Hotze; David P Strachan; John A Curtin; Klaus Bønnelykke; Chao Tian; Atsushi Takahashi; Jorge Esparza-Gordillo; Alexessander Couto Alves; Jacob P Thyssen; Herman T den Dekker; Manuel A Ferreira; Elisabeth Altmaier; Patrick Ma Sleiman; Feng Li Xiao; Juan R Gonzalez; Ingo Marenholz; Birgit Kalb; Maria Pino Yanes; Cheng-Jian Xu; Lisbeth Carstensen; Maria M Groen-Blokhuis; Cristina Venturini; Craig E Pennell; Sheila J Barton; Albert M Levin; Ivan Curjuric; Mariona Bustamante; Eskil Kreiner-Møller; Gabrielle A Lockett; Jonas Bacelis; Supinda Bunyavanich; Rachel A Myers; Anja Matanovic; Ashish Kumar; Joyce Y Tung; Tomomitsu Hirota; Michiaki Kubo; Wendy L McArdle; A J Henderson; John P Kemp; Jie Zheng; George Davey Smith; Franz Rüschendorf; Anja Bauerfeind; Min Ae Lee-Kirsch; Andreas Arnold; Georg Homuth; Carsten O Schmidt; Elisabeth Mangold; Sven Cichon; Thomas Keil; Elke Rodríguez; Annette Peters; Andre Franke; Wolfgang Lieb; Natalija Novak; Regina Fölster-Holst; Momoko Horikoshi; Juha Pekkanen; Sylvain Sebert; Lise L Husemoen; Niels Grarup; Johan C de Jongste; Fernando Rivadeneira; Albert Hofman; Vincent Wv Jaddoe; Suzanne Gma Pasmans; Niels J Elbert; André G Uitterlinden; Guy B Marks; Philip J Thompson; Melanie C Matheson; Colin F Robertson; Janina S Ried; Jin Li; Xian Bo Zuo; Xiao Dong Zheng; Xian Yong Yin; Liang Dan Sun; Maeve A McAleer; Grainne M O'Regan; Caoimhe Mr Fahy; Linda E Campbell; Milan Macek; Michael Kurek; Donglei Hu; Celeste Eng; Dirkje S Postma; Bjarke Feenstra; Frank Geller; Jouke Jan Hottenga; Christel M Middeldorp; Pirro Hysi; Veronique Bataille; Tim Spector; Carla Mt Tiesler; Elisabeth Thiering; Badri Pahukasahasram; James J Yang; Medea Imboden; Scott Huntsman; Natàlia Vilor-Tejedor; Caroline L Relton; Ronny Myhre; Wenche Nystad; Adnan Custovic; Scott T Weiss; Deborah A Meyers; Cilla Söderhäll; Erik Melén; Carole Ober; Benjamin A Raby; Angela Simpson; Bo Jacobsson; John W Holloway; Hans Bisgaard; Jordi Sunyer; Nicole M Probst Hensch; L Keoki Williams; Keith M Godfrey; Carol A Wang; Dorret I Boomsma; Mads Melbye; Gerard H Koppelman; Deborah Jarvis; Wh Irwin McLean; Alan D Irvine; Xue Jun Zhang; Hakon Hakonarson; Christian Gieger; Esteban G Burchard; Nicholas G Martin; Liesbeth Duijts; Allan Linneberg; Marjo-Riitta Jarvelin; Markus M Noethen; Susanne Lau; Norbert Hübner; Young-Ae Lee; Mayumi Tamari; David A Hinds; Daniel Glass; Sara J Brown; Joachim Heinrich; David M Evans; Stephan Weidinger
Journal:  Nat Genet       Date:  2015-10-19       Impact factor: 38.330

View more
  14 in total

1.  The Immunogenetics of Acne.

Authors:  Mohamed L Elsaie; Dalia G Aly
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  An Atopic Dermatitis-Like Mouse Model by Alternate Epicutaneous Application of Dinitrofluorobenzene and an Extract of Dermatophagoides Farinae.

Authors:  Shujing Feng; Wengying Liu; Sisi Deng; Guoxuan Song; Jie Zhou; Zhengni Zheng; Zhiqiang Song
Journal:  Front Med (Lausanne)       Date:  2022-06-15

3.  OVOL1 Regulates Psoriasis-Like Skin Inflammation and Epidermal Hyperplasia.

Authors:  Peng Sun; Remy Vu; Morgan Dragan; Daniel Haensel; Guadalupe Gutierrez; Quy Nguyen; Elyse Greenberg; Zeyu Chen; Jie Wu; Scott Atwood; Eric Pearlman; Yuling Shi; Wei Han; Kai Kessenbrock; Xing Dai
Journal:  J Invest Dermatol       Date:  2020-12-14       Impact factor: 8.551

4.  Potential effect of fish oil to preserve expression of cell cycle and tight junction regulating genes in colon after di-isononyl phthalate ingestion in albino Wistar rats.

Authors:  Ahmed S Ahmed; Hoda A Ibrahim; Ehab M Hantash
Journal:  Eur J Histochem       Date:  2021-05-31       Impact factor: 3.188

Review 5.  Critical Points on the Use of Biologicals in Allergic Diseases and Asthma.

Authors:  Ioana Agache; Catalina Cojanu; Alexandru Laculiceanu; Liliana Rogozea
Journal:  Allergy Asthma Immunol Res       Date:  2020-01       Impact factor: 5.764

Review 6.  Tralokinumab for the Treatment of Atopic Dermatitis.

Authors:  Egídio Freitas; Emma Guttman-Yassky; Tiago Torres
Journal:  Am J Clin Dermatol       Date:  2021-06-21       Impact factor: 7.403

Review 7.  The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis.

Authors:  Lai-San Wong; Yu-Ta Yen; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 8.  Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.

Authors:  Masutaka Furue
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

9.  Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

Authors:  A Wollenberg; A Blauvelt; E Guttman-Yassky; M Worm; C Lynde; J-P Lacour; L Spelman; N Katoh; H Saeki; Y Poulin; A Lesiak; L Kircik; S H Cho; P Herranz; M J Cork; K Peris; L A Steffensen; B Bang; A Kuznetsova; T N Jensen; M L Østerdal; E L Simpson
Journal:  Br J Dermatol       Date:  2020-12-30       Impact factor: 9.302

Review 10.  New and Emerging Systemic Treatments for Atopic Dermatitis.

Authors:  Megan Newsom; Arjun M Bashyam; Esther A Balogh; Steven R Feldman; Lindsay C Strowd
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.